Breast Cancer Research and Treatment

, Volume 73, Issue 3, pp 237–243

Inhibition of NF-κB Activity Decreases the VEGF mRNA Expression in MDA-MB-231 Breast Cancer Cells

  • Arihiro Shibata
  • Takashi Nagaya
  • Tsuneo Imai
  • Hiroomi Funahashi
  • Akimasa Nakao
  • Hisao Seo
Article

Abstract

VEGF (vascular endothelial growth factor) secreted from tumor cells including breast cancer serves as a potent angiogenic factor which favors tumor growth and metastasis. Indeed, a higher concentration of serum VEGF has been shown to associate with a poorer prognosis in patients with breast cancer. On the other hand, constitutive expression of a transcription factor, NF-κB was correlated with progression and metastasis in a number of human breast cancers, suggesting a possible regulation of VEGF expression by NF-κB. We thus investigated the relationship between the expression of VEGF and constitutive NF-κB activity in three breast cancer cell lines, MCF-7, T47D, and MDA-MB-231. The basal levels of VEGF mRNA expression correlated with those of nuclear NF-κB activity in these cell lines. The highest NF-κB activity in MDA-MB-231 cells was associated with the highest expression of VEGF mRNA, while the activity and the mRNA levels were moderate in MCF cells and the lowest in T47D cells. In MDA-MB-231 cells, inhibition of NF-κB by adenovirus-mediated expression of a dominant negative NF-κB or by a proteasome inhibitor, MG132, decreased the VEGF mRNA. These results suggest that NF-κB is involved in the upregulation of VEGF mRNA and inhibition of the activity could be a new approach for the treatment of breast cancer by preventing angiogenesis.

adenovirus angiogenesis breast cancer NF-κB proteasome inhibitor VEGF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31, 1995Google Scholar
  2. 2.
    Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442–447, 1987Google Scholar
  3. 3.
    Silver BJ: Platelet-derived growth factor in human malignancy. Biofactors 3: 217–227, 1992Google Scholar
  4. 4.
    Klagsbrun M: Mediators of angiogenesis: the biological signi-ficance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin Cancer Biol 3: 81–87, 1992Google Scholar
  5. 5.
    Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844, 1993Google Scholar
  6. 6.
    Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985, 1983Google Scholar
  7. 7.
    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309, 1989Google Scholar
  8. 8.
    Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1–8, 1991Google Scholar
  9. 9.
    Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120–1124, 1992Google Scholar
  10. 10.
    Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H: Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 53: 161–166, 1999Google Scholar
  11. 11.
    Rosen L: Antiangiogenic strategies and agents in clinical trials. Oncologist 5: 20–27, 2000Google Scholar
  12. 12.
    Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066–1071, 1997Google Scholar
  13. 13.
    Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE: Aberrant nuclear factorkappaB/ Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952–2960, 1997Google Scholar
  14. 14.
    Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629–3639, 1997Google Scholar
  15. 15.
    Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787–789, 1996Google Scholar
  16. 16.
    Wang CY, Mayo MW, Baldwin Jr AS: TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 274: 784–787, 1996Google Scholar
  17. 17.
    Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE: Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. Embo J 15: 4682–4690, 1996Google Scholar
  18. 18.
    Nagaya T, Fujieda M, Otsuka G, Yang JP, Okamoto T, Seo H: A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. J Clin Invest 106: 393–402, 2000Google Scholar
  19. 19.
    Nagaya T, Jameson JL: Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem 268: 15766–15771, 1993Google Scholar
  20. 20.
    Fujita T, Nolan GP, Ghosh S, Baltimore D: Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev 6: 775–787, 1992Google Scholar
  21. 21.
    Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159, 1987Google Scholar
  22. 22.
    Nagaya T, Murata Y, Yamaguchi S, Nomura Y, Ohmori S, Fujieda M, Katunuma N, Yen PM, Chin WW, Seo H: Intracellular proteolytic cleavage of 9-cis-retinoic acid receptor alpha by cathepsin L-type protease is a potential mechanism for modulating thyroid hormone action. J Biol Chem 273: 33166–33173, 1998Google Scholar
  23. 23.
    Otsuka G, Nagaya T, Saito K, Mizuno M, Yoshida J, Seo H: Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res 59: 4446–4452, 1999Google Scholar
  24. 24.
    McGrory WJ, Bautista DS, Graham FL: A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163: 614–617, 1988Google Scholar
  25. 25.
    Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59–74, 1977Google Scholar
  26. 26.
    Kikumori T, Kambe F, Nagaya T, Imai T, Funahashi H, Seo H: Activation of transcriptionally active nuclear factor-kappaB by tumor necrosis factor-alpha and its inhibition by antioxidants in rat thyroid FRTL-5 cells. Endocrinology 139: 1715–1722, 1998Google Scholar
  27. 27.
    Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ: Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334–5339, 2000Google Scholar
  28. 28.
    Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17: 4015–4023, 1997Google Scholar
  29. 29.
    Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947–11954, 1991Google Scholar
  30. 30.
    Zabel U, Schreck R, Baeuerle PA: DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. J Biol Chem 266: 252–260, 1991Google Scholar
  31. 31.
    Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, Van Waes C: Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 7: 435–442, 2001Google Scholar
  32. 32.
    Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ: A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. Embo J 12: 3551–3558, 1993Google Scholar
  33. 33.
    Perkins ND, Agranoff AB, Pascal E, Nabel GJ: An interaction between the DNA-binding domains of RelA (p65) and Sp1 mediates human immunodeficiency virus gene activation. Mol Cell Biol 14: 6570–6583, 1994Google Scholar
  34. 34.
    Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F: A novel complex between the p65 subunit of NFkappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. Embo J 11: 205–213, 1992Google Scholar
  35. 35.
    Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395–405, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Arihiro Shibata
    • 1
    • 2
  • Takashi Nagaya
    • 1
  • Tsuneo Imai
    • 2
  • Hiroomi Funahashi
    • 2
  • Akimasa Nakao
    • 2
  • Hisao Seo
    • 1
  1. 1.Department of Endocrinology and Metabolism, Division of Molecular and Cellular AdaptationResearch Institute of Environmental MedicineJapan
  2. 2.The Second Department of Surgery, School of MedicineNagoya UniversityNagoyaJapan

Personalised recommendations